Lorenzo Falchi, MD
Lymphoma Specialist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- All non-Hodgkin and Hodgkin Lymphomas
- Follicular Lymphoma
- Diffuse Large B-Cell Lymphoma
Request an Appointment
About Me
- Assistant Attending Physician
As a board-certified medical oncologist and hematologist, I have been passionately dedicated to the study and treatment of blood diseases for well over a decade with a long-standing focus on the care of people with lymphoma. My practice benefits from years of experience that I gained while working at prestigious institutions.
Read more
At MSK, I am fortunate to be part of a multidisciplinary team of experts who share a deep commitment to developing effective therapies for all people with lymphoma. Our staff also provides an exceptional level of care and support for every one of our patients from the first point of contact, so that they are never alone during their time at MSK.
I am also deeply involved in conducting patient-centered research. At MSK, we offer one of the largest clinical trial portfolios for people with all types of lymphoma. I am especially interested in understanding how lymphoma interacts with the immune system. If we know how we can harness the immune system to fight lymphoma, we can develop new immunotherapies that can be used alone or in combination.
A lymphoma diagnosis can be overwhelming and terrifying. Most of my patients are naturally concerned about their future. I am convinced that the first step towards cure is defeating fear. That is why my priority is to clear up uncertainties by providing both information and education at every visit. I also believe that each person is unique, and my goal is to offer personalized care plans, while using the most effective and innovative treatments available today.
A lymphoma specialist is a doctor with special training in diagnosing and treating lymphoma.
My Specialties
- All non-Hodgkin and Hodgkin Lymphomas
- Follicular Lymphoma
- Diffuse Large B-Cell Lymphoma
- Marginal Zone Lymphoma
- Hodgkin Lymphoma
- Mantle Cell Lymphoma
- Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia
- Peripheral T-Cell Lymphoma
- Burkitt Lymphoma
- Clinical Trials Research
- Immunotherapy
- Novel Therapeutic Agents
- Personalized Therapy
Education
- MD, University of Perugia
Residencies
- Internal Medicine - Yale-New Haven Hospital
Awards and Honors
- Best Research Fellow for the Leukemia Fellowship Program, MD Anderson Cancer Center (2013)
- Celgene Future Leaders in Hematology Award
- American Society of Hematology Abstract Achievement Award (2018)
Fellowships
- Medical Oncology - University of Perugia, Italy
- Leukemia - MD Anderson Cancer Center
- Hematology/Oncology - NewYork-Presbyterian Hospital/Columbia University Medical Center
Board Certifications
- Internal Medicine
- Hematology
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Falchi sees patients at two locations.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Falchi
- A Phase I Study of RO7443904 in Combination with Glofitamab for People with Non-Hodgkin Lymphoma
- A Phase IA/II Study of Epcoritamab in People with B-Cell Non-Hodgkin Lymphoma
- A Phase II Study of Glofitamab Immunotherapy plus R-CHOP for People with Diffuse Large B-Cell Lymphoma
- A Phase II Study of Mosunetuzumab as Initial Chemotherapy-Free Treatment for Follicular Lymphoma
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Falchi L, Vardhana SA, Salles GA. Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities. Blood. 2023 Feb 2;141(5):467-480. doi: 10.1182/blood.2021011994.
Falchi L, Ma H, Klein S, Lue JK, Montanari F, Marchi E, Deng C, Kim HA, Rada A, Jacob AT, Kinahan C, Francescone MM, Soderquist CR, Park DC, Bhagat G, Nandakumar R, Menezes D, Scotto L, Sokol L, Shustov AR, O’Connor OA. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood. 2021 Apr 22;137(16):2161-2170. doi: 10.1182/blood.2020009004. Erratum in: Blood. 2022 Mar 10;139(10):1600. PMID: 33171487.
Falchi L, Sawas A, Deng C, Amengual JE, Colbourn DS, Lichtenstein EA, Khan KA, Schwartz LH, O’Connor OA. High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy. J Hematol Oncol. 2016 Nov 30;9(1):132. doi: 10.1186/s13045-016-0363-1. PMID: 27899158; PMCID: PMC5129196.
Read more
Falchi L, Keating MJ, Marom EM, Truong MT, Schlette EJ, Sargent RL, Trinh L, Wang X, Smith SC, Jain N, Estrov Z, O’Brien S, Wierda WG, Lerner S, Ferrajoli A. Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood. 2014 May 1;123(18):2783-90. doi: 10.1182/blood-2013-11-536169. Epub 2014 Mar 10. PMID: 24615780; PMCID: PMC4123418.
Visit PubMed for a full listing of Dr. Falchi’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Lorenzo Falchi discloses the following relationships and financial interests:
-
ADC Therapeutics
Professional Services and Activities -
AbbVie
Professional Services and Activities -
AstraZeneca
Professional Services and Activities -
GenMab
Professional Services and Activities -
Genentech
Professional Services and Activities
-
Physicians' Education Resource
Professional Services and Activities -
Projects In Knowledge
Professional Services and Activities -
Seagen
Professional Services and Activities -
Taylor & Francis Group
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
